Skip to main content
. 2022 Jun 6;21:96. doi: 10.1186/s12933-022-01523-7

Table 2.

Clinical and biological characteristics according to CAD severity

Characteristics Total (n = 731) Single-vessel CAD (n = 260) Multi-vessel CAD (n = 471) P-value
Age (years) 63 (58, 68) 63 (57, 68) 63 (58, 69) 0.361
Sex (M/F) 1.42 1.10 1.65 0.009
SBP (mmHg) 140 (127, 156) 140 (126, 154) 141 (127, 156) 0.225
DBP (mmHg) 83 (76, 91) 83 (76, 90) 83 (76, 91) 0.944
BMI (kg/m2) 26.67 ± 3.90 26.47 ± 3.75 26.86 ± 3.91 0.077
Drinking 253 (34.6%) 91 (35.0%) 162 (34.4%) 0.506
Smoking 363 (49.7%) 123 (47.3%) 240 (51.0%) 0.084
TC (mg/dL) 4.61 (3.87, 5.43) 4.45 (3.78, 5.21) 4.69 (3.92, 5.63) 0.018
TG (mg/dL) 1.51 (1.11, 2.17) 1.42 (1.05, 2.04) 1.57 (1.14, 2.21) 0.018
HDL-C (mg/dL) 1.05 (0.88, 1.24) 1.10 (0.92, 1.32) 1.03 (0.87, 1.21) 0.002
LDL-C (mg/dL) 2.72 (2.14, 3.39) 2.63 (2.02, 3.20) 2.80 (2.19, 3.50) 0.002
FPG (mmol/L) 6.44 (5.53, 8.66) 5.98 (5.28, 7.34) 6.71 (5.66, 9.40)  < 0.001
HbA1c (%) 6.1 (5.6, 7.0) 6.0 (5.5, 6.5) 6.2 (5.7, 7.3)  < 0.001
TyG index 7.42 (7.04, 7.94) 7.32 (6.93, 7.75) 7.52 (7.10, 8.06)  < 0.001
Glucose metabolism state
 NGR 93 (12.7%) 45 (17.3%) 48 (10.2%)  < 0.001
 Pre-DM 265 (36.3%) 113 (43.5%) 152 (32.3%)
 DM 373 (51.0%) 102 (39.2%) 271 (57.5%)
Drug therapy
 Antihypertensive 545 (74.6%) 196 (75.4%) 349 (74.1%) 0.461
 Antilipidemic 561 (76.7%) 198 (76.2%) 363 (77.1%) 0.518
 Antiplatelet 708 (96.9%) 246 (94.6%) 462 (98.1%) 0.010

Data are presented as mean ± standard deviation or median (interquartile range) or number (proportion, %)

M, male; F, female; TyG, triglyceride glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NGR, normal glucose regulation; Pre-DM, prediabetes mellitus; DM, diabetes mellitus